On January 18, the FDA approved trastuzumab-dttb (Ontruzant, Samsung Bioepis), a biosimilar to trastuzumab (Herceptin), for the treatment of patients with HER2-overexpressing breast cancer or metastatic gastric or gastroesophageal junction adenocarcinoma.
Read the OncLive news coverage here.
Posted 1/18/19
From mental health concerns to fertility preservation, adolescents and young adults with cancer require a specialized approach to treatment and survivorship care. In honor of Childhood Cancer Awareness Month, ACCC highlights a pivotal program from the University of North Carolina Lineberger Comprehensive Cancer Center and resources that meet the critical needs of these patients.
